IRIS
DEL MASTRO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 29.368
NA - Nord America 5.363
AS - Asia 4.894
Continente sconosciuto - Info sul continente non disponibili 1.223
SA - Sud America 458
AF - Africa 125
OC - Oceania 17
Totale 41.448
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.219
US - Stati Uniti d'America 4.974
SG - Singapore 1.750
CN - Cina 1.140
BD - Bangladesh 747
VN - Vietnam 712
FR - Francia 337
FI - Finlandia 276
BR - Brasile 260
HK - Hong Kong 198
CA - Canada 155
DE - Germania 138
NL - Olanda 92
GB - Regno Unito 82
AR - Argentina 70
JP - Giappone 59
ES - Italia 55
MX - Messico 53
ID - Indonesia 42
IN - India 42
JM - Giamaica 35
CO - Colombia 33
EC - Ecuador 32
IQ - Iraq 27
RU - Federazione Russa 26
CH - Svizzera 25
PH - Filippine 25
HN - Honduras 24
MW - Malawi 23
CR - Costa Rica 22
VE - Venezuela 22
SV - El Salvador 20
ZA - Sudafrica 20
CL - Cile 18
GT - Guatemala 18
AU - Australia 17
SA - Arabia Saudita 17
TR - Turchia 17
AT - Austria 15
BE - Belgio 14
EG - Egitto 14
IE - Irlanda 14
MY - Malesia 14
NI - Nicaragua 14
PK - Pakistan 13
TH - Thailandia 13
DZ - Algeria 12
MA - Marocco 12
TT - Trinidad e Tobago 12
KE - Kenya 11
PR - Porto Rico 11
PY - Paraguay 10
SE - Svezia 10
NP - Nepal 9
PL - Polonia 9
UA - Ucraina 8
UZ - Uzbekistan 8
KR - Corea 7
LB - Libano 7
RO - Romania 7
TW - Taiwan 7
BS - Bahamas 6
RS - Serbia 5
TN - Tunisia 5
UY - Uruguay 5
BB - Barbados 4
CG - Congo 4
DO - Repubblica Dominicana 4
JO - Giordania 4
KZ - Kazakistan 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BO - Bolivia 3
CI - Costa d'Avorio 3
EE - Estonia 3
IL - Israele 3
IR - Iran 3
KW - Kuwait 3
LY - Libia 3
NO - Norvegia 3
PE - Perù 3
PT - Portogallo 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
CU - Cuba 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
MK - Macedonia 2
OM - Oman 2
PS - Palestinian Territory 2
Totale 40.192
Salva come PNG Salva come JPEG
Città #
Genova 12.582
Genoa 9.899
Rapallo 2.503
Vado Ligure 2.270
San Jose 1.056
Singapore 851
Ashburn 699
Council Bluffs 288
Lauterbourg 284
Helsinki 256
New York 213
Ho Chi Minh City 211
Beijing 199
Hong Kong 178
Santa Clara 161
Hanoi 156
Los Angeles 102
Boardman 96
Bordighera 95
Frankfurt am Main 93
Phoenix 89
Milan 86
Rome 69
Chicago 60
Buffalo 58
Tokyo 52
Amsterdam 46
Dallas 46
Naples 44
Haiphong 33
Houston 32
São Paulo 30
Da Nang 29
Mexico City 29
Bologna 28
Boston 28
Toronto 28
Orem 27
Atlanta 26
Kingston 24
Philadelphia 23
Miami 22
Tianjin 22
Bar Harbor 20
Charlotte 20
Madrid 19
Lappeenranta 18
San Salvador 18
Brasília 17
San José 17
Zurich 17
Brooklyn 16
Montreal 16
Washington 16
Bari 15
Guangzhou 15
St Louis 15
Turin 15
Barcelona 14
Curitiba 14
Dublin 14
Guatemala City 14
Hải Dương 14
Quito 14
San Antonio 14
Brescia 13
Des Moines 13
Las Vegas 13
Managua 13
Newark 13
Orlando 13
Palermo 13
Schiffdorf 13
The Bronx 13
City of London 12
Columbus 12
Florence 12
Houten 12
Minneapolis 12
Phủ Lý 12
Seattle 12
Shenzhen 12
Cincinnati 11
Detroit 11
London 11
Baghdad 10
Cleveland 10
Enfield 10
Melbourne 10
Piscataway 10
Queens 10
Shanghai 10
Surrey 10
Taranto 10
Venice 10
Verona 10
Bangkok 9
Biên Hòa 9
Bogotá 9
Denver 9
Totale 33.867
Salva come PNG Salva come JPEG
Nome #
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† 478
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 315
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 258
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. 255
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 246
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 233
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 228
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 211
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 210
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 210
Cancer and fertility preservation: international recommendations from an expert meeting 209
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 205
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 201
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 200
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 197
Management of young women with early breast cancer 194
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 192
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 191
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 191
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial 189
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 188
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 186
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 186
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 186
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 186
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer 186
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 184
Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients 183
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 182
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 182
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 182
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 181
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 176
A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes 176
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 175
Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes 173
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 173
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial 172
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 172
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 172
News on the medical treatment of young women with early-stage HER2-negative breast cancer 171
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 171
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 171
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 171
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 170
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 168
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 168
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. 168
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 168
Treatment with aromatase inhibitors and markers of cardiovascular disease 167
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 166
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer 166
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 165
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 165
Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates 164
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 164
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity 164
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial 163
Taxane-containing chemotherapy in the treatment of early breast cancer patients 163
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 163
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study 162
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 162
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology 161
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 161
Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence 160
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole 160
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis 159
Optimization of a wga-free molecular tagging-based ngs protocol for ctcs mutational profiling 159
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 158
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 157
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 156
A case where switching end points for clinical trial interpretation might be the right choice 156
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group 156
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 156
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 156
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. 156
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 155
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 155
Targeting bone metastatic cancer: Role of the mTOR pathway 154
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 154
Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies 153
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 153
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives 153
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors 153
Letrozole withdrawal response in locally advanced breast cancer 153
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy 153
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer 152
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 151
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 150
Predicting mood disorders in breast cancer patients. 150
Anthracycline-free therapy for HER2-amplified breast cancer 150
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 150
Fertility, sexuality and cancer in young adult women 149
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis 148
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations 148
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study 147
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 147
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 146
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy 145
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 144
Totale 17.698
Salva come PNG Salva come JPEG
Categoria #
all - tutte 146.956
article - articoli 146.671
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 285
Totale 293.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.454 0 0 128 261 73 302 97 616 279 247 96 355
2022/20233.079 274 249 31 283 448 457 79 379 507 27 305 40
2023/20241.831 72 227 55 250 145 191 127 154 80 106 110 314
2024/20255.998 194 442 159 382 725 711 494 956 295 340 594 706
2025/202614.648 1.232 517 1.623 1.154 1.594 1.017 1.997 710 1.029 1.450 1.014 1.311
2026/20272.582 1.330 618 634 0 0 0 0 0 0 0 0 0
Totale 41.448